Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | ATP4A | P20648 | 3/20 | 0.33 |
| ▸ | ATP4B | P51164 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22801148 | 0.87 | TDP1 (0.38) | CYP3A4TDP1SMN1; SMN2ALOX15TP53 | |
| SCHEMBL4996802 | 0.83 | IDO1 (0.38) | CYP3A4TDP1SMN1; SMN2ALOX15TP53 | |
| SCHEMBL1922648 | 0.83 | APLNR (0.35) | SMN1; SMN2BACE1ALDH1A1NPC1RAB9A | |
| SCHEMBL1289637 | 0.81 | IDO1 (0.44) | CYP3A4TDP1SMN1; SMN2THRBTAAR1 | |
| SCHEMBL28530955 | 0.81 | AMY1A (0.45) | TDP1ALOX15TP53BACE1ALDH1A1 | |
| SCHEMBL19915790 | 0.79 | FNTA (0.34) | BACE1ALDH1A1MAPT | |
| SCHEMBL3940682 | 0.78 | BACE1 (0.44) | BACE1ALDH1A1IDO1 | |
| SCHEMBL2103775 | 0.78 | HTT (0.44) | CYP3A4TDP1SMN1; SMN2ALOX15THRB | |
| SCHEMBL22801136 | 0.76 | KDM4E (0.46) | CYP3A4SMN1; SMN2ALOX15TP53BACE1 | |
| SCHEMBL22822209 | 0.76 | BACE1 (0.32) | CYP3A4BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655269-B2 | Prodrug-type anticancer agent using cancer-specific enzymatic activity | THE UNIVERSITY OF TOKYO (JP) | 2023-05-23 | — | — | US | disclosed |
| US-11655269-B2 | Prodrug-type anticancer agent using cancer-specific enzymatic activity | THE UNIVERSITY OF TOKYO (JP) | 2023-05-23 | — | — | US | disclosed |
| US-11655269-B2 | Prodrug-type anticancer agent using cancer-specific enzymatic activity | THE UNIVERSITY OF TOKYO (JP) | 2023-05-23 | — | — | US | disclosed |
| US-20200399305-A1 | PRODRUG-TYPE ANTICANCER AGENT USING CANCER-SPECIFIC ENZYMATIC ACTIVITY | THE UNIVERSITY OF TOKYO (JP) | 2020-12-24 | — | — | US | disclosed |
| US-20200399305-A1 | PRODRUG-TYPE ANTICANCER AGENT USING CANCER-SPECIFIC ENZYMATIC ACTIVITY | THE UNIVERSITY OF TOKYO (JP) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655269-B2 | Prodrug-type anticancer agent using cancer-specific enzymatic activity | GUSB, NTPCR, FOLH1 | CYP3A4 489/4885TDP1 358/4885SMN1; SMN2 3375/4885 |
| US-20200399305-A1 | PRODRUG-TYPE ANTICANCER AGENT USING CANCER-SPECIFIC ENZYMATIC ACTIVITY | GUSB, NTPCR, FOLH1 | CYP3A4 489/4885TDP1 358/4885SMN1; SMN2 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.